Add checks (#6)

* Add Workflows => Use global

* fix typo

* fix typo

Co-authored-by: Yuri05 <Yuri05@github.com>

.github/workflows/MarkdownLinksCheck.yml

@@ -0,0 +1,12 @@
+name: Check Markdown links
+
+on: 
+  push:
+    branches:
+      - review
+
+jobs:
+  markdown-link-check:
+    uses: Open-Systems-Pharmacology/Workflows/.github/workflows/MarkdownLinksCheck.yml@main
+    with:
+      folder-path: 'Evaluation/report'

.github/workflows/SpellChecker.yml

@@ -0,0 +1,8 @@
+name: Spellcheck
+
+on: 
+  [push, pull_request]
+
+jobs:
+  Spellcheck:
+    uses: Open-Systems-Pharmacology/Workflows/.github/workflows/SpellChecker.yml@main

.github/workflows/XRefCheck.yml

@@ -0,0 +1,12 @@
+name: XRefCheck
+
+on: 
+  push:
+    branches:
+      - review
+
+jobs:
+  crossref-check-without-anchors:
+    uses: Open-Systems-Pharmacology/Workflows/.github/workflows/XRefCheck.yml@main
+    with:
+      ignored-folders: 'Evaluation/Input'

.github/workflows/wordlist.txt

@@ -0,0 +1 @@
+nda

Evaluation/Input/Content/Section2.2_Data.md

@@ -59,7 +59,7 @@ The metabolic pattern was determined as shown in the following table.
 
 ** to sum up to the values of metabolic quantifications from the table above (73.93% + 2.09%)
 
-*** The fraction excretion to feces of unchanged dapagliflozin of 18.90% (see above) was added and distributed proportionally to dapagliflozin-3-O-glucuronide and dapagliflozin-2-O-glucuronide under the assumption that the measured fraction of unchanged dapagliflozin resulted from originally glucuronidated metabolites that underwent biliary excretion and subsequent degradation to dapagliflozin by bacterial glucurinodases in feces.
+*** The fraction excretion to feces of unchanged dapagliflozin of 18.90% (see above) was added and distributed proportionally to dapagliflozin-3-O-glucuronide and dapagliflozin-2-O-glucuronide under the assumption that the measured fraction of unchanged dapagliflozin resulted from originally glucuronidated metabolites that underwent biliary excretion and subsequent degradation to dapagliflozin by bacterial glucuronidases in feces.
 
 The following table shows the final mass balance data used for model building under the assumption of that unchanged dapagliflozin molecules in feces were originally glucuronides. Please refer to [Section 2.3](#23-model-parameters-and-assumptions) for rationale.
 

Evaluation/Input/Content/Section2.3_Model_Parameters_and_Assumptions.md

@@ -6,7 +6,7 @@ During model building, two different "data scenarios" regarding mass balance inf
 
 **Scenario 1**: The measured fraction excreted to feces as unchanged drug of approx. 19% resulted from incomplete absorption (assuming f<sub>a</sub>  ~ 0.81).
 
-**Scenario 2**:  The measured fraction excretion to feces of unchanged dapagliflozin resulted from originally glucuronidated metabolites that underwent biliary excretion and subsequent degradation to dapagliflozin by bacterial glucurinodases in feces (assuming f<sub>a</sub> ~ 1). The cleavage of hepatobiliary secreted glucuronides to the aglycone (e.g. parent drug) by beta-glucuronidases in the colon was reported previously ([Blaut 2013](#5-references), [Molly 1993](#5-references), [Possemiers 2004](#5-references), [Sakamoto 2002](#5-references)). 
+**Scenario 2**:  The measured fraction excretion to feces of unchanged dapagliflozin resulted from originally glucuronidated metabolites that underwent biliary excretion and subsequent degradation to dapagliflozin by bacterial glucuronidases in feces (assuming f<sub>a</sub> ~ 1). The cleavage of hepatobiliary secreted glucuronides to the aglycone (e.g. parent drug) by beta-glucuronidases in the colon was reported previously ([Blaut 2013](#5-references), [Molly 1993](#5-references), [Possemiers 2004](#5-references), [Sakamoto 2002](#5-references)). 
 
 Scenario 1 did not allow to find a good description of the pharmacokinetic data. Thus, scenario 2 was used during further model building. Note that this increased the fraction metabolized via UGT1A9 and UGT2B7.
 
@@ -24,7 +24,7 @@ The reported blood to plasma ratio of 0.88 ([Obermeier 2009](#5-references)) was
 
 ### 2.3.3 Metabolism and Elimination
 
-As previously described in [Section 2.2.2](#222-clinical-data),  mass balance data ([Kasichayanula 2008](#5-references), [Obermeier 2009](#5-references), [Kasichayanula 2014](#5-references)) indicated that UGT1A9 is predominatly responsible for the metabolism of dapagliflozin to dapagliflozin-3-O-glucuronide. A minor fraction is metabolized via UGT2B7 to dapagliflozin-2-O-glucuronide and via oxidative cyotochrome-P450 enzymes.
+As previously described in [Section 2.2.2](#222-clinical-data),  mass balance data ([Kasichayanula 2008](#5-references), [Obermeier 2009](#5-references), [Kasichayanula 2014](#5-references)) indicated that UGT1A9 is predominatly responsible for the metabolism of dapagliflozin to dapagliflozin-3-O-glucuronide. A minor fraction is metabolized via UGT2B7 to dapagliflozin-2-O-glucuronide and via oxidative cytochrome-P450 enzymes.
 
 In summary, three metabolic first order routes were implement into the model: